Antibody pressure by a human monoclonal antibody targeting the 2009 pandemic H1N1 virus hemagglutinin drives the emergence of a virus with increased virulence in mice

mBio

Volumn 3, Issue 3, 2012, Pages

  O'Donnell, Christopher D ^a   Vogel, Leatrice ^a   Wright, Amber ^a,d   Das, Suman R ^a,e   Wrammert, Jens ^b   Li, Gui Mei ^b   Mccausland, Megan ^b   Zheng, Nai Ying ^c   Yewdell, Jonathan W ^a   Ahmed, Rafi ^b   Wilson, Patrick C ^c   Subbaraoa, Kanta ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e J CRAIG VENTER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2,3 SIALIC ACID RECEPTOR; HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY EM4C04; INFLUENZA VIRUS HEMAGGLUTININ; RECEPTOR; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ANTIGENIC DRIFT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; EPITOPE MAPPING; ESCAPE MUTATION; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE EVASION; IN VITRO STUDY; IN VIVO STUDY; LETHALITY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; VIRUS CELL INTERACTION; VIRUS MUTANT; VIRUS MUTATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS VIRULENCE;

INFLUENZA A VIRUS; MUS;

EID: 84863425227     PISSN: None     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00120-12     Document Type: Article

References (54)

1. Wright PF, Neumann G, Kawaoka Y. 2007. Orthomyxoviruses, p 1691-1740. In Knipe DM, et al. (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Couch RB, Kasel JA. 1983. Immunity to influenza in man. Annu. Rev. Microbiol. 37:529-549.
3. Potter CW, Oxford JS. 1979. Determinants of immunity to influenza infection in man. Br. Med. Bull. 35:69-75.
4. Epstein SL, et al. 1993. Beta 2-microglobulin-deficient mice can be protected against influenzaAinfection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. J. Immunol. 150:5484-5493.
5. Martinez O, Tsibane T, Basler CF. 2009. Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery. Int. Rev. Immunol. 28:69-92.
6. Gerhard W. 2001. The role of the antibody response in influenza virus infection. Curr. Top. Microbiol. Immunol. 260:171-190.
7. Gerhard W. 1976. The analysis of the monoclonal immune response to influenza virus. II. The antigenicity of the viral hemagglutinin. J. Exp. Med. 144:985-995.
8. Palese P, Shaw ML. 2007. Orthomyxoviridae: the viruses and their replication, p 1647-1689. In Knipe DM, et al. (ed), Fields virology, vol 2, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
9. Hensley SE, et al. 2009. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 326:734-736.
10. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. 1982. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31:417-427.
11. Raymond FL, Caton AJ, Cox NJ, Kendal AP, Brownlee GG. 1983. Antigenicity and evolution amongst recent influenza viruses ofH1N1subtype. Nucleic Acids Res. 11:7191-7203.
12. Horimoto T, Kawaoka Y. 2005. Influenza: lessons from past pandemics, warnings from current incidents. Nat. Rev. Microbiol. 3:591-600.
13. Kawaoka Y, Krauss S, Webster RG. 1989. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J. Virol. 63:4603-4608.
14. Garten RJ, et al. 2009. Antigenic and genetic characteristics of swineorigin 2009 A(H1N1) influenza viruses circulating in humans. Science 325:197-201.
15. Mak GC, et al. 2010. Association of D222G substitution in haemagglutinin of 2009 pandemic influenza A (H1N1) with severe disease. Euro Surveill. 15:19534. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19534.
16. Kilander A, Rykkvin R, Dudman SG, Hungnes O. 2010. Observed association between the HA1 mutation D222G in the 2009 pandemic influenza A(H1N1) virus and severe clinical outcome, Norway 2009-2010. Euro Surveill. 15:19498. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19498.
17. World Health Organization. 2009. Public health significance of virus mutation detected in Norway pandemic (H1N1) 2009. Pandemic (H1N1) 2009 briefing note 17. http://www.who.int/csr/disease/swineflu/notes/briefing_20091120/en/.
18. Chen H, et al. 2010. Quasispecies of the D225G substitution in the hemagglutinin of pandemic influenza A(H1N1) 2009 virus from patients with severe disease in Hong Kong, China. J. Infect. Dis. 201:1517-1521.
19. Ikonen N, et al. 2010. Genetic diversity of the 2009 pandemic influenza A(H1N1) viruses in Finland. PLoS One 5:e13329. http://dx.doi.org/10.1371/journal.pone.0013329.
20. Wrammert J, et al. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208:181-193.
21. Brownlee GG, Fodor E. 2001. The predicted antigenicity of the haemagglutinin of the 1918 Spanish influenza pandemic suggests an avian origin. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:1871-1876.
22. Yang H, Carney P, Stevens J. 2010. Structure and receptor binding properties of a pandemic H1N1 virus hemagglutinin. PLoS Curr. 2:RRN1152. http://dx.doi.org/10.1371/currents.RRN1152.
23. Das SR, et al. 2010. Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain. PLoS Pathog. 6:e1001211. http://dx.doi.org/10.1371/journal.ppat.1001211.
24. Tsuchiya E, et al. 2002. Effect of addition of new oligosaccharide chains to the globular head of influenza A/H2N2 virus haemagglutinin on the intracellular transport and biological activities of the molecule. J. Gen. Virol. 83:1137-1146.
25. Wei CJ, et al. 2010. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci. Transl. Med. 2:24ra21. http://dx.doi.org/10.1126/scitranslmed.3000799.
26. Ye J, et al. 2010. Variations in the hemagglutinin of the 2009 H1N1 pandemic virus: potential for strains with altered virulence phenotype? PLoS Pathog. 6:e1001145. http://dx.doi.org/10.1371/journal.ppat.1001145.
27. Ilyushina NA, et al. 2010. Adaptation of pandemic H1N1 influenza viruses in mice. J. Virol. 84:8607-8616.
28. Skehel JJ, Wiley DC. 2000. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69: 531-569.
29. Connor RJ, Kawaoka Y, Webster RG, Paulson JC. 1994. Receptor specificity in human, avian, and equineH2andH3influenza virus isolates. Virology 205:17-23.
30. Rogers GN, Paulson JC. 1983. Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology 127:361-373.
31. Glaser L, Conenello G, Paulson J, Palese P. 2007. Effective replication of human influenza viruses in mice lacking a major alpha2,6 sialyltransferase. Virus Res. 126:9-18.
32. Ning ZY, et al. 2009. Detection of expression of influenza virus receptors in tissues of BALB/c mice by histochemistry. Vet. Res. Commun. 33:895-903.
33. Keleta L, Ibricevic A, Bovin NV, Brody SL, Brown EG. 2008. Experimental evolution of human influenza virus H3 hemagglutinin in the mouse lung identifies adaptive regions in HA1 and HA2. J. Virol. 82: 11599-11608.
34. Krause JC, et al. 2011. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J. Virol. 85:10905-10908.
35. Whittle JR, et al. 2011. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc. Natl. Acad. Sci. U. S. A. 108:14216-14221.
36. Manicassamy B, et al. 2010. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog. 6:e1000745. http://dx.doi.org/10.1371 /journal.ppat.1000745.
37. Krause JC, et al. 2010. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenzaA(H1N1) viruses. J. Virol. 84:3127-3130.
38. Chutinimitkul S, et al. 2010. Virulence-associated substitution D222G in the hemagglutinin of 2009 pandemic influenza A(H1N1) virus affects receptor binding. J. Virol. 84:11802-11813.
39. Liu Y, et al. 2010. Altered receptor specificity and cell tropism of D222G hemagglutinin mutants isolated from fatal cases of pandemic A(H1N1) 2009 influenza virus. J. Virol. 84:12069-12074.
40. Korteweg C, Gu J. 2008. Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am. J. Pathol. 172: 1155-1170.
41. van Riel D, et al. 2006. H5N1 virus attachment to lower respiratory tract. Science 312:399.
42. Shinya K, et al. 2006. Avian flu: influenza virus receptors in the human airway. Nature 440:435-436.
43. Beigel JH, et al. 2005. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 353:1374-1385.
44. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. 2008. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358:261-273.
45. Wang TT, Parides MK, Palese P. 2012. Seroevidence for H5N1 influenza infections in humans: meta-analysis. Science 335:1463.
46. Powell TJ, et al. 2012. Identification of H5N1-specific T-cell responses in a high-risk cohort in Vietnam indicates the existence of potential asymptomatic infections. J. Infect. Dis. 205:20-27.
47. Nicholls JM, et al. 2007. Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat. Med. 13:147-149.
48. Uiprasertkul M, et al. 2005. Influenza A H5N1 replication sites in humans. Emerg. Infect. Dis. 11:1036-1041.
49. Taubenberger JK, Morens DM. 2006. 1918 Influenza: the mother of all pandemics. Emerg. Infect. Dis. 12:15-22.
50. Kuroda M, et al. 2010. Characterization of quasispecies of pandemic 2009 influenza A virus (A/H1N1/2009) by de novo sequencing using a nextgeneration DNA sequencer. PLoS One 5:e10256. http://dx.doi.org/10.1371/journal.pone.0010256.
51. Suguitan AL, et al. 2006. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 3:e360. http://dx.doi.org/10.1371/journal.pmed.0030360.
52. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
53. Chen GL, et al. 2011. Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets. J. Infect. Dis. 203:930-936.
54. Lau YF, Tang LH, McCall AW, Ooi EE, Subbarao K. 2010. An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice. J. Virol. 84: 8639-8649.